JOURNAL ARTICLE

Bristol's Outlook Tops Views as New Drugs Gain Momentum.

  • Published In: Bloomberg.com, 2026. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Smith, Gerry 3 of 3

Abstract

The article focuses on Bristol Myers Squibb Co.'s positive financial outlook for 2026, forecasting sales and profits that exceed Wall Street expectations, despite anticipated losses from older drugs losing patent protection. The company expects total sales between $46 billion and $47.5 billion for the year, with adjusted earnings per share projected at $6.05 to $6.35. Bristol is banking on newer treatments like Reblozyl and Camzyos to offset revenue declines from established products such as Eliquis and Opdivo, which are facing increased competition and price cuts. Additionally, the company is implementing cost reductions and is awaiting results from significant clinical trials that could impact its future growth. [Extracted from the article]

Additional Information

  • Source:Bloomberg.com. 2026/02, pN.PAG
  • Document Type:Article
  • Subject Area:Business and Management
  • Publication Date:2026
  • Accession Number:191381163
  • Copyright Statement:Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.